Octagon Capital Advisors LP Raises Stock Position in Regulus Therapeutics Inc. (NASDAQ:RGLS)

Octagon Capital Advisors LP increased its holdings in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 13.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,848,802 shares of the biopharmaceutical company's stock after buying an additional 585,101 shares during the period. Regulus Therapeutics comprises approximately 1.3% of Octagon Capital Advisors LP's investment portfolio, making the stock its 24th largest holding. Octagon Capital Advisors LP owned approximately 7.40% of Regulus Therapeutics worth $7,661,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Jane Street Group LLC acquired a new position in Regulus Therapeutics in the 3rd quarter valued at $46,000. Barclays PLC raised its stake in Regulus Therapeutics by 285.2% in the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company's stock valued at $132,000 after purchasing an additional 62,549 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Regulus Therapeutics by 193.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company's stock valued at $124,000 after purchasing an additional 52,059 shares during the last quarter. Renaissance Technologies LLC raised its stake in Regulus Therapeutics by 20.5% in the 4th quarter. Renaissance Technologies LLC now owns 117,100 shares of the biopharmaceutical company's stock valued at $185,000 after purchasing an additional 19,900 shares during the last quarter. Finally, PEAK6 LLC acquired a new position in Regulus Therapeutics in the 4th quarter valued at $95,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Wells Fargo & Company reissued an "equal weight" rating and issued a $9.00 price objective on shares of Regulus Therapeutics in a research note on Thursday, May 1st. Leerink Partnrs downgraded Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research note on Friday, March 14th. Leerink Partners reaffirmed a "market perform" rating and issued a $7.00 target price on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Finally, Canaccord Genuity Group reaffirmed a "hold" rating and issued a $11.00 target price (down from $28.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $8.50.

Regulus Therapeutics Stock Performance

Shares of NASDAQ RGLS traded up $0.02 during mid-day trading on Friday, reaching $7.87. 860,014 shares of the company's stock were exchanged, compared to its average volume of 891,053. The firm has a market capitalization of $544.87 million, a price-to-earnings ratio of -7.36 and a beta of 0.49. Regulus Therapeutics Inc. has a 52-week low of $0.83 and a 52-week high of $8.20. The company's 50-day moving average is $3.41 and its 200-day moving average is $2.10.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.14. As a group, equities analysts predict that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current fiscal year.

Regulus Therapeutics Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.